175 related articles for article (PubMed ID: 23469971)
1. Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.
Chu YW; Polson A
Future Oncol; 2013 Mar; 9(3):355-68. PubMed ID: 23469971
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
Polson AG; Calemine-Fenaux J; Chan P; Chang W; Christensen E; Clark S; de Sauvage FJ; Eaton D; Elkins K; Elliott JM; Frantz G; Fuji RN; Gray A; Harden K; Ingle GS; Kljavin NM; Koeppen H; Nelson C; Prabhu S; Raab H; Ross S; Slaga DS; Stephan JP; Scales SJ; Spencer SD; Vandlen R; Wranik B; Yu SF; Zheng B; Ebens A
Cancer Res; 2009 Mar; 69(6):2358-64. PubMed ID: 19258515
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugate technology development for hematologic disorders.
Bander NH; Czuczman MS; Younes A
Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
[TBL] [Abstract][Full Text] [Related]
4. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
5. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
6. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
7. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
Sapra P; Betts A; Boni J
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
[TBL] [Abstract][Full Text] [Related]
9. Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.
Janthur WD; Cantoni N; Mamot C
Int J Mol Sci; 2012 Nov; 13(12):16020-45. PubMed ID: 23443108
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
[TBL] [Abstract][Full Text] [Related]
11. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates: current status and future directions.
Perez HL; Cardarelli PM; Deshpande S; Gangwar S; Schroeder GM; Vite GD; Borzilleri RM
Drug Discov Today; 2014 Jul; 19(7):869-81. PubMed ID: 24239727
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
15. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
Herrera AF; Molina A
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
[TBL] [Abstract][Full Text] [Related]
16. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
[TBL] [Abstract][Full Text] [Related]
17. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
[TBL] [Abstract][Full Text] [Related]
18. Single-chain immunotoxins targeted to CD40 for the treatment of human B-lineage hematologic malignancies.
Francisco JA; Siegall CB
Leuk Lymphoma; 1998 Jul; 30(3-4):237-45. PubMed ID: 9713956
[TBL] [Abstract][Full Text] [Related]
19. Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment.
Li Z; Wang M; Yao X; Li H; Li S; Liu L; Yu D; Li X; Fang J; Huang C
Int Immunopharmacol; 2018 Sep; 62():299-308. PubMed ID: 30048860
[TBL] [Abstract][Full Text] [Related]
20. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.
Robak T; Robak E
Expert Opin Investig Drugs; 2014 Jul; 23(7):911-24. PubMed ID: 24708159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
